Armata Retained Earnings Total Equity from 2010 to 2025
| ARMP Stock | USD 1.58 0.07 4.24% |
Retained Earnings Total Equity | First Reported 2010-12-31 | Previous Quarter -215.8 M | Current Value -226.6 M | Quarterly Volatility 23.2 M |
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Selling General Administrative of 12.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
Armata | Retained Earnings Total Equity |
Latest Armata Pharmaceuticals' Retained Earnings Total Equity Growth Pattern
Below is the plot of the Retained Earnings Total Equity of Armata Pharmaceuticals over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Armata Pharmaceuticals' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Retained Earnings Total Equity | 10 Years Trend |
|
Retained Earnings Total Equity |
| Timeline |
Armata Retained Earnings Total Equity Regression Statistics
| Arithmetic Mean | (193,844,377) | |
| Geometric Mean | 192,645,854 | |
| Coefficient Of Variation | (11.95) | |
| Mean Deviation | 19,445,768 | |
| Median | (179,702,000) | |
| Standard Deviation | 23,172,261 | |
| Sample Variance | 537T | |
| Range | 60.1M | |
| R-Value | (0.77) | |
| Mean Square Error | 237.5T | |
| R-Squared | 0.59 | |
| Significance | 0.0005 | |
| Slope | (3,729,443) | |
| Total Sum of Squares | 8054.3T |
Armata Retained Earnings Total Equity History
About Armata Pharmaceuticals Financial Statements
Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Retained Earnings Total Equity | -215.8 M | -226.6 M |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.